The Mode of Bone Morphogenetic Protein (BMP) Receptor Oligomerization Determines Different BMP-2 Signaling Pathways

Abstract

Bone morphogenetic proteins (BMPs) are multifunctional proteins regulating cell growth, differentiation, and apoptosis. BMP-2 signals via two types of receptors (BRI and BRII) that are expressed at the cell surface as homomeric as well as heteromeric complexes. Prior to ligand binding, a low but measurable level of BMP-receptors is found in preformed hetero-oligomeric complexes. The major fraction of the receptors is recruited into hetero-oligomeric complexes only after ligand addition. For this, BMP-2 binds first to the high affinity receptor BRI and then recruits BRII into the signaling complex. However, ligand binding to the preformed complex composed of BRII and BRI is still required for signaling, suggesting that it may mediate activating conformational changes. Using several approaches we have addressed the following questions: (i) Are preformed complexes incompetent of signaling in the absence of BMP-2? (ii) Which domains of the BRII receptors are essential for this complex formation? (iii) Are there differences in signals sent from BMP-induced versus preformed receptor complexes? By measuring the activation of Smads, of p38 MAPK and of alkaline phosphatase, we show that the ability of kinase-deficient BRII receptor mutants to inhibit BMP signaling depends on their ability to form heteromeric complexes with BRI. Importantly, a BRII mutant that is incapable in forming preassembled receptor complexes but recruits into a BMP-induced receptor complex does not interfere with the Smad pathway but does inhibit the induction of alkaline phosphatase as well as p38 phosphorylation. These results indicate that signals induced by binding of BMP-2 to preformed receptor complexes activate the Smad pathway, whereas BMP-2-induced recruitment of receptors activates a different, Smad-independent pathway resulting in the induction of alkaline phosphatase activity via p38 MAPK.Bone morphogenetic proteins (BMPs) 1 are members of the transforming growth factor-␤ (TGF-␤) superfamily that play important roles in most morphogenetic processes during development (1). BMPs are able to induce the formation of bone at nonbony sites in the adult animal by influencing the differentiation of mesenchymal progenitor cells along the cartilage lineage pathway. BMPs act on osteoblasts as well as chondrocytes but also on many other cell types such as neuronal cells (2, 3). Signaling by BMP-2 involves two types of transmembrane serine/threonine kinases, termed type I (BRI) and type II (BRII) receptors (4 -8). Receptors of both types are needed to form a functional complex to initiate further signaling events. Activated BMP type I receptors phosphorylate Smad1, Smad5, and Smad8 (R-Smads), which then assemble into heteromeric complexes with Smad4 (Co-Smad) and translocate into the nucleus to regulate transcription of target genes (9, 10). In addition, BMP receptors initiate other signaling pathways, distinct from the Smad pathway, resulting in the activation of p38 MAPK and JNK (11-13).We have shown recently that the oligomerization pattern of ...

PICK1 promotes caveolin-dependent degradation of TGF-β type I receptor

“…As shown in Figure 3G, PICK1 interacted with TβRII only when TβRI was co-expressed. As overexpressed receptors can form a complex in the absence of TGF-β [36,37], these results implicate that PICK1 associates with TβRII through TβRI. …”

A novel R486Q mutation in BMPR1B resulting in either a brachydactyly type C/symphalangism-like phenotype or brachydactyly type A2

“…The HA epitope was integrated at the N-terminus (extracellular) of each receptor. 9 Luciferase reporter gene assay C2C12 cells stably expressing WT Bmpr1b, R486Q-Bmpr1b or R486W-Bmpr1b were transfected with BRE luciferase reporter construct (p(BRE)4-luc), 16 renilla luciferase (pRLTK) (Promega GmbH, Mannheim) as an internal control for transfection efficiency using Lipofectaminet (Invitrogen GmbH, Karlsruhe, Germany). Cells were starved for 5 h in DMEM containing 0.5% FCS and stimulated for 16 -24 h with increasing amounts of recombinant GDF5 under starving conditions.…”

Recombinant growth/differentiation factor‐5 (GDF‐5) stimulates osteogenic differentiation of marrow mesenchymal stem cells in porous hydroxyapatite ceramic

“…However, because both of these receptors are used by several members of the BMP/ GDF family of ligands, the gene-knockout phenotypes of these ligands resemble a very distinct phenotype, and it is evident that additional receptors or coreceptors that specify distinct signaling cascades are expressed. 13,14 In the current study, we incorporated recombinant mouse GDF-5, comparing with recombinant human BMP-2, into composites of mesenchymal cells and porous HA, to qualitatively and quantitatively confirm the osteogenic potential of the composites. The analyses used were histological as well as biochemical measuring of bone-specific parameters at the protein and gene expression levels.…”